Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $53.52 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.